Trial halted: Dual-Attack cancer treatment fails to launch
NCT ID NCT06084689
Summary
This study aimed to test the safety and effectiveness of a two-drug combination (Ezabenlimab and BI 907828) for people with advanced, hard-to-treat cancers that had spread. It was designed for adults with specific types of soft tissue sarcoma, lung, breast, colorectal, or biliary tract cancer whose tumors had certain biological features. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Poitiers
Poitiers, France
-
Centre Eugène Marquis
Rennes, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Institut Bergonié
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.